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(54) Title: 3 -OXOPIPERAZINIUM DERIVATIVES AS AGONISTS OF NERVE GROWTH FACTOR AND THEIR USE AS 
MEDICAMENTS 
(57) Abstraet: New 3-oxopiperazinium derivatives agonists ofNerve Growth Factor receptors and their use as medicaments. Neu-
rotrophin binding to its specific receptor Trk A leads to the activation of multiple signalling cascades, culminating in neuroregen-
erative effects, incIuding neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of sever-
al neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life 
and their side effects. Small molecule neurotrophin peptidomimetics may be beneficial in treating a number of neurodegenerative 
disorders. The present invention shows the capacity of nerve growth factor agonist molecules derived from the 3- oxopiperazinium 
scaffold to induce differentiation in PC12 cells and, therefore, that these small molecules with NGF agonist activity may be bene-
ficial for treatment of neurodegenerative diseases, due to their neuroregenerative effects. 























































